Skip to main content
Fig. 3 | Respiratory Research

Fig. 3

From: Usage of compromised lung volume in monitoring steroid therapy on severe COVID-19

Fig. 3

Quantitative CT parameters over time in the steroid therapy group and the standard care group. A %CL, compromised lung volume, considered as the sum of %PAL and %NNL; P < 0.001 for change over time; P = 0.01 for between-group difference. B %NNL, percentage of nonaerated lung volume; P = 0.08 for change over time; P = 0.09 for between-group difference. C %PAL, percentage of poorly aerated lung volume; P < 0.001 for change over time; P = 0.006 for between-group difference. D %NAL, percentage of normally aerated lung volume; P = 0.04 for change over time; P = 0.13 for between-group difference. E %HI, percentage of hyperinflated lung volume; P < 0.001 for change over time; P = 0.002 for between-group difference. P values for between-group difference were calculated by repeated-measures analysis of variance (ANOVA). The trends over time in quantitative CT parameters were also assessed using repeated-measures ANOVA. SIDAK multiple comparisons correction was used to compare each stage against the baseline (T1). * denotes a significant difference between two groups at each stage. # denotes a significant difference in the steroid therapy group when comparing each stage against the baseline (T1). † denotes a significant difference in the standard care group when comparing each stage against the baseline (T1). All CT scans were classified into five stages according to the interval between hospital admission and follow-up CT scans: Stage 1 (T1, at admission); Stage 2 (T2, 3–7 days); Stage 3 (T3, 8–14 days); Stage 4 (T4, 15–21 days); and Stage 5 (T5, 22–31 days)

Back to article page